SCANCELL HOLDINGS PLC — Director's Dealing 2019

Dec 17, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1881X

Scancell Holdings Plc

17 December 2019

17 December 2019

Scancell Holdings plc

("Scancell" or the "Company")

Director's Dealings

Scancell, the developer of novel immunotherapies for the treatment of cancer, today announces that Vulpes Life Science Fund, a person closely associated with Martin Diggle, Non- Executive Director, has purchased 2,925,000 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 16 December 2019 at a price of 5.2p per share. Following the purchase Vulpes Life Science Fund holds 80,549,311 ordinary shares representing 17.3% of the company.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Vulpes Life Science Fund

2

Reason for the notification

a)

Position/status

Person closely associated with Martin Diggle, Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Scancell Holdings plc

b)

LEI

2138008RXEG856SNP666

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 0.1 pence each

b)

Nature of Transaction

Purchase of Ordinary shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
5.2 pence	2,925,000

d)

Aggregated information

-      Aggregated volume

-      Price

N/A (single transaction)

e)

Date of transaction

16 December 2019

f)

Place of transaction

Outside a trading venue

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For Further Information:

Scancell Holdings plc
Dr John Chiplin, Chairman		+44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		+44 (0) 20 7886 2500
FTI Consulting Simon Conway/Natalie Garland-Collins		+44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·       SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·       SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website:  www.scancell.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHCKODQBBDDDBD